PILAR BARRETINA GINESTA

Oncología de Precisión de Girona

Slomovitz BM, Cibula D, Lv W, Ortaç F, Hietanen S, Backes F, Kikuchi A, Lorusso D, Danska-Bidzinska A, Samouëlian V, Barretina-Ginesta MP, Vulsteke C, Lai CH, Pothuri B, Zhang Y, Magallanes-Maciel M, Amit A, Guarneri V, Zagouri F, Bell M, Welz J, Eminowicz G, Hruda M, J Willmott L, Lichfield J, Wang W, Orlowski R, Aktan G, Gladieff L, Van Gorp T

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43, 251-259 dx.doi.org/10.1200/JCO-24-01887

Oncología de Precisión de Girona

Graybill WS, Vergote I, Pothuri B, Anttila M, O'Malley DM, Lorusso D, Haggerty AF, Fabbro M, Chan JK, Heitz F, Willmott LJ, Bruchim I, Zhuo Y, Estévez-García P, Monk BJ, Denys H, Knudsen A, Tinker AV, Sánchez LM, Provencher D, Barretina-Ginesta MP, Hartman J, Booth DV, González-Martín A

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2025, 14 dx.doi.org/10.57264/cer-2024-0133

Oncología de Precisión de Girona

Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

GYNECOLOGIC ONCOLOGY, 2025, 192, 128-136 dx.doi.org/10.1016/j.ygyno.2024.12.003

Oncología de Precisión de Girona

Masvidal Hernandez M, Cros Costa S, Salvador Coloma C, Quilez Cutillas A, Barretina-Ginesta MP, Cotes Sanchís A

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27, 417-424 dx.doi.org/10.1007/s12094-024-03609-y

Oncología de Precisión de Girona

Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

CLINICAL CANCER RESEARCH, 2024, 30, 176-186 dx.doi.org/10.1158/1078-0432.CCR-23-0771

Oncología de Precisión de Girona

Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

ANNALS OF ONCOLOGY, 2024, 35, 414-428 dx.doi.org/10.1016/j.annonc.2024.02.006

Oncología de Precisión de Girona

Vulsteke, C, Chambers, SK, Pérez, MJR, Chan, JK, Raaschou-Jensen, N, Zhuo, Y, Lorusso, D, Herzog, TJ, Rouge, TD, Pepin, JAT, Braicu, EI, Chen, LM, Levy, T, Barter, JF, Barretina-Ginesta, MP, Joosens, E, York, W, Malinowska, IA, González-Martín, A, Monk, BJ

Tolerability of the niraparib individualized starting dose in the PRIMA/ ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

EUROPEAN JOURNAL OF CANCER, 2024, 208, 114157-114157 dx.doi.org/10.1016/j.ejca.2024.114157

Oncología de Precisión de Girona

Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Bmc Cancer, 2024, 24, 911-911 dx.doi.org/10.1186/s12885-024-12700-0

Oncología de Precisión de Girona

Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

Bmc Cancer, 2024, 24, 876-876 dx.doi.org/10.1186/s12885-024-12501-5

Oncología de Precisión de Girona

Perez-Fidalgo, JA, Gálvez-Montosa, F, Guerra, EM, Madariaga, A, Manzano, A, Martin-Lorente, C, Rubio-Pérez, MJ, Alarcón, J, Barretina-Ginesta, MP, Gaba, L

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26, 2758-2770 dx.doi.org/10.1007/s12094-024-03531-3

Directori

Publicacions

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature.

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

Tolerability of the niraparib individualized starting dose in the PRIMA/ ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023)

Formulari de contacte

Conoce el IDIBGI!